FDA Approves Mirikizumab-Mrkz for Crohn’s Disease, Expanding Its Use To The Second Major Type Of Inflammatory Bowel Disease
The U.S. Food and Drug Administration (FDA) has approved Mirikizumab-mrkz for the treatment of moderately to severely active Crohn’s disease in adults. This marks its second approv...
Read →